Delong Liu
Hematology & Oncology · Hawthorne, NYNPI 1538122932
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $348,073 of the $519,950 with a category attached, or 66.9%. 32 manufacturers reported payments, led by Beigene USA, Inc. at 31.8% of the total. Reporting peaked in 2019 at $124,139 and has fallen 52.7% since, to $58,755 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $1155.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$165K
- Rigel Pharmaceuticals, Inc.$86K
- Astellas Pharma US Inc$83K
- Incyte Corporation$64K
- Beone Medicines USA, Inc.$28K
- AstraZeneca$17K
- plus $77K from 26 others
Across 70 payments — averaging $7467.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$378K
- Eli Lilly$58K
- Acerta Pharma LLC$22K
- Janssen Research & Development, LLC$21K
- Rigel Pharmaceuticals, Inc.$15K
- Incyte Corporation$11K
- plus $17K from 5 others
What the payments were for
- Consulting fees$99,71119%
- Speaking & faculty fees$348,07367%
- Travel & lodging$58,67611%
- Food & beverage$13,4413%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 123 | $165,117 |
| Rigel Pharmaceuticals, Inc. | 60 | $85,625 |
| Astellas Pharma US Inc | 70 | $83,162 |
| Incyte Corporation | 47 | $63,782 |
| Beone Medicines USA, Inc. | 14 | $28,377 |
| AstraZeneca | 28 | $16,602 |
| Pharmacyclics LLC, An Abbvie Company | 16 | $12,281 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $12,223 |
| Pharmaessentia USA Corporation | 9 | $9,517 |
| Novartis | 9 | $7,714 |
| Sanofi | 7 | $7,386 |
| E.r. Squibb & Sons, L.L.C. | 15 | $6,789 |
| Johnson & Johnson | 8 | $4,683 |
| Jazz Pharmaceuticals Inc. | 8 | $4,045 |
| Geron Corporation | 7 | $3,333 |
| GSK | 1 | $2,600 |
| Taiho Oncology, Inc. | 2 | $2,113 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $1,845 |
| Beigene (suzhou) Co., Ltd. | 1 | $1,268 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Exelixis Inc. | 2 | $200 |
| Servier Pharmaceuticals LLC | 1 | $140 |
| Bristol Myers Squibb | 1 | $134 |
| Amgen | 1 | $118 |
| Boehringer Ingelheim | 3 | $76 |
| Gilead | 1 | $52 |
| EMD Serono, Inc. | 1 | $41 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Kadmon Pharmaceuticals LLC | 1 | $22 |
| Merck | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $11 |
| Pfizer | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$519,950 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 35 | $725,733 |
| JakafiRuxolitinib Phosphate | 35 | $597,213 |
| PomalystPomalidomide | 20 | $434,586 |
| BrukinsaZanubrutinib | 22 | $313,548 |
| TasignaNilotinib Hcl | 12 | $278,091 |
| ScemblixAsciminib Hydrochloride | 12 | $251,727 |
| XareltoRivaroxaban | 13 | $9,326 |
| EliquisApixaban | 14 | $7,449 |
| Cyclosporine ModifiedCyclosporine, Modified | 19 | $2,689 |
| Fluconazole | 52 | $1,793 |
| Imatinib Mesylate | 13 | $1,182 |
| Acyclovir | 78 | $1,104 |
| Hydroxyurea | 30 | $675 |
| Ciprofloxacin Hcl | 23 | $238 |
| Dexamethasone | 11 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $134 | $725,73335 claims |
| Incyte CorporationJakafi | $63,782 | $597,21335 claims |
| NovartisTasigna, Scemblix | $7,714 | $529,81724 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $6,789 | $434,58620 claims |
| Beigene USA, Inc.Brukinsa | $165,117 | $313,54822 claims |
| Johnson & JohnsonXarelto | $4,683 | $9,32613 claims |
| PfizerEliquis | $5 | $7,44914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Hawthorne
- Karen SeiterHawthorne$593K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.